I’ve tested my DNA at both http://www.familytreedna.com and at http://www.23andme.com Because I am adopted, I used the Family Finder test at familytreedna to verify my paper trail. I waited until I knew who my biological father was and even until I had talked to his son on the phone. In fact, I never had to bring up the subject. His son told me that a DNA test would prove my theory and said that he would be willing to take one. I ordered the test for him and it proved correctly that we are 1/2 siblings.
But DNA testing can show so much more. It seems like everyone I talk to believes that they have some Native American blood. I thought I did also as I have dark hair and eyes. And my complexion is “olive” or “ruddy”. I had to look up the definition of ruddy to make sure I was using it correctly & I am. But I found that my ancestry composition is 99.9% European and .1% East Asian & Native American.
(of a person’s face) Having a healthy red color.
At 23andme, it is about finding your relatives, but also about your health & how your genes determine your chances for disease. Under “My Health”, 23andme has the following categories — disease risk, carrier status and drug response.
One of the most interesting things I discovered is that 3.1% of my DNA is from Neanderthals. That puts me in the upper 98% percentile. Average Northern Europeans on their site have an average of 2.6% Neanderthal. Being in the upper 2% is like being in an exclusive group like Mensa, only with much more hair. I always wondered why my toes made my feet look like they belonged to a Hobbit. 23andme also sells t-shirts that correspond with the correct Neanderthal percentage.
23andme recently acquired new financing that allows them to permanently lower their test from $290.00 to $99.00. This is an incredible bargain. Their goal is to attract one million new customers this year. That will make matching with relatives so much easier.
I’ve copied the following from 23andme’s Press Release of Dec. 11, 2012.
23andMe Raises More Than $50 Million in New Financing
Company Sets Growth Goal Of One Million Customers, Reduces Price to $99 from $299
MOUNTAIN VIEW, Calif. – December 11, 2012 – 23andMe, Inc., the leading personal genetics company, today announced it has raised more than $50 million in a Series D financing. Participants in the financing include Yuri Milner, a new investor, as well as existing investors Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. This investment will help the company achieve its growth goal of one million customers.
The Power of One Million People
Expanding the company’s ability to reach and serve one million individuals supports 23andMe’s goal to revolutionize health and wellness. It also will accelerate 23andMe’s ability to create a powerful platform that enables researchers around the globe to make meaningful discoveries significantly faster than is currently possible. With this expansion, 23andMe, which currently has more than 180,000 customers, will aim to:
- Enable groundbreaking research by creating an exponentially larger collective of actively engaged, genotyped individuals;
- Help accelerate development of new treatments;
- Improve understanding of wellness and disease prevention; and
- Broaden access for people seeking to manage their health and well-being through direct access and greater understanding of their own genetic data.
“A community of one million actively engaged individuals will be transformational for research. A community of this magnitude will improve researchers’ ability to quickly answer questions about genetic function and the role of environmental factors. In addition, it will enable researchers to understand medication efficacy and side effects, in both medications that exist today and medications are that are in development,” Wojcicki added.
Broadening Access: Lowering Price to $99
The Series D investment, combined with rapidly decreasing costs associated with genetic testing technologies, enables 23andMe to reduce the price of its Personal Genome Service to $99, effective immediately. The company will continue to evaluate optimal pricing strategies.
The investment also enables 23andMe to expand the necessary infrastructure to support growth in its research and operational capabilities, including product development, genetic research, software development, recruitment and marketing.